PT-141 (Bremelanotide)
Melanocortin receptor agonist (Bremelanotide/Vyleesi®) studied for central sexual arousal pathways via MC3R/MC4R in the hypothalamus. FDA-approved for hypoactive sexual desire disorder. Acts on desire (brain) not blood flow — distinct mechanism from PDE5 inhibitors.
Lo que Muestra la Investigación
Studied for MC3R/MC4R-mediated central sexual arousal via hypothalamic and mesolimbic dopamine pathways. FDA-approved Phase III human trial data available (n=394). Studies measure satisfying sexual events, FSFI score, and intromission latency (animal). Most clinically validated peptide in this guide.
Pros y Contras
- +Only FDA-approved peptide drug specifically for sexual dysfunction — most complete human safety and efficacy dataset of any peptide on this site
- +Central mechanism (brain-driven desire) vs. peripheral mechanism (blood flow) — targets a different and complementary pathway to PDE5 inhibitors
- +Studied in both men and women — unusually broad clinical applicability
- +Relatively fast onset: peak plasma concentration in 45–60 minutes, with effects reported within 1–2 hours
- +Available as a pre-filled autoinjector (Vyleesi®) in the USA — demonstrates commercial viability
- +Phase III placebo-controlled trial data available in public literature
- −Nausea is the most common side effect — reported in approximately 40% of participants in Phase III trials, sometimes severe enough to require a separate anti-nausea medication
- −Flushing and hyperpigmentation (temporary skin darkening) reported at higher doses
- −Blood pressure can temporarily increase — contraindicated in cardiovascular disease
- −LATAM-accessible vendor availability is very limited — most list PT-141 as out of stock or not carried
- −Subcutaneous injection required — no oral form with established efficacy
- −Not approved by EMA; LATAM self-researchers face significant sourcing barriers
Cronología de Efectos
Basado en cronologías de estudios publicados. La extrapolación humana es aproximada — los resultados individuales varían significativamente.
Phase III clinical trial data shows measurable improvement in satisfying sexual events and desire scores within the 24-hour period following a single dose. Animal model effects (intromission latency, lordosis quotient) are measurable within 45–60 minutes of administration.
Para Qué se Investiga
Preguntas Prácticas
How does PT-141 compare to Viagra or Cialis for men?
PDE5 inhibitors (Viagra, Cialis) work by increasing blood flow to the penis — they address the physical mechanics of erection but cannot improve sexual desire. PT-141 works upstream in the brain, activating desire and arousal pathways through melanocortin receptors. For men whose primary issue is low desire or psychological arousal rather than vascular function, PT-141 addresses a component that PDE5 inhibitors cannot. The two have different — and potentially complementary — mechanisms.
How can I manage the nausea side effect?
Nausea is the primary dose-limiting side effect of PT-141. The Phase III trial protocol allowed participants to use 8 mg ondansetron (Zofran) as a pre-treatment 30 minutes before PT-141 injection — this significantly reduced nausea incidence. Starting with the lowest effective dose and injecting in the evening (when nausea can be slept through if it occurs) are practical approaches reported in the self-research community. Taking the injection on an empty stomach vs. with food does not consistently affect nausea in published data.
Dónde Comprar PT-141 (Bremelanotide) en Latinoamérica
1 proveedor accesible para LATAM tiene PT-141 (Bremelanotide) actualmente disponible en stock. Compara precios y disponibilidad abajo.